FDA Brief

Warning letters Drugs

FDA warning letter to

Nexus Health Solutions LLC dba Harper Meds

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

What happened

FDA reviewed Harper Meds' website, https://www.harpermeds.com, in March 2026 and found it offers compounded semaglutide and tirzepatide drug products. FDA said the site's labels show "Harper Meds" as if the company made the drugs when it does not, compares the products to Ozempic and Wegovy, and says they come from "FDA-licensed 503A Outsourcing Facilities." FDA called these statements false or misleading, which makes the drugs misbranded (labeled or promoted in a way the law forbids).

What FDA found

  1. The product labels pictured on the website name Harper Meds as the maker, suggesting it compounds the drugs when it does not.

    FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; 21 C.F.R. § 201.1(h)(2)
  2. The site says compounded semaglutide has the "same active ingredient as Ozempic & Wegovy," which implies the compounded drugs are FDA-approved or reviewed for safety and effectiveness when they are not.

    FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. The site calls its suppliers "FDA-licensed 503A Outsourcing Facilities," but FDA does not approve or license compounding pharmacies or outsourcing facilities, so the claim is false.

    FD&C Act sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]; sections 503A/503B [21 U.S.C. §§ 353a, 353b]
  4. Shipping these misbranded drugs across state lines is a prohibited act.

    FD&C Act section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA tells the company to write to its Office of Compounding Quality and Compliance within 15 business days with the steps taken to fix the violations and prevent them from recurring. The reply should name the entities that make the compounded drugs, include a sample of their labeling, and show that the misleading website claims were corrected or removed.

Who should pay attention

  • telehealth and online pharmacies selling compounded semaglutide or tirzepatide
  • compounding pharmacies and 503A/503B facilities whose products are resold by others
  • marketing teams and agencies that write drug product website copy

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low